Cronos Group Inc (CRON)
2.07
0.00 (0.00%)
USD |
NASDAQ |
Nov 15, 11:38
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 791.32M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 3.50% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 7.759 |
Price to Book Value | 0.747 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 92.95% |
Profile
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition. |
URL | https://www.thecronosgroup.com |
Investor Relations URL | https://ir.thecronosgroup.com/ |
HQ State/Province | Ontario |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Nov. 12, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the US, the company has an option to acquire 5.9% of US multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition. |
URL | https://www.thecronosgroup.com |
Investor Relations URL | https://ir.thecronosgroup.com/ |
HQ State/Province | Ontario |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Growth |
Next Earnings Release | Feb. 28, 2025 (est.) |
Last Earnings Release | Nov. 12, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |